GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

bluebird bio

CRISPR Therapeutics

Gilead Sciences

Sarepta Therapeutics

Vertex Pharmaceuticals

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.

Gene therapy: Why does it cost millions for a single treatment?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S, today announced it will release its fourth quarter and full year 2023 financial results before U.S. markets open on Thursday, February 29, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To.

GoodRx Announces Date for Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

The consensus price target hints at a 27.8% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in GoodRx Holdings, Inc. (GDRX)? Wall Street Analysts Think 27.83%

During flu season, you want to be on top of your strategy on how to quickly get better if you're sick. Each month, PYMNTS tracks the most popular mobile apps in the prescription space for the Provider Ranking of Prescription Apps.

GoodRx Leads Provider Ranking of Prescription Apps for Sixth Straight Month

GoodRx has a strong value proposition that drives continuous adoption, offering cost savings and price comparisons on medications. The company benefits from a strong network effect, with consumers, PBMs, and pharmacies incentivized to join the network, leading to increased volume and market share. While growth may be weak in the short term, the company has potential for margin expansion and is positioned for long-term success.

GoodRx: Cost Saving Is A Strong Value Proposition To Consumers

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings, today announced its intention to refinance its first lien credit facilities. The Company is seeking to refinance its first lien term loan facility and concurrently amend its revolving credit facility to extend the maturity date. The terms of the proposed refinancing, if any, will be disclosed upon the completion of the transaction, which is e.

GoodRx Announces Proposed Refinancing of First Lien Credit Facilities

Does GoodRx Holdings, Inc. (GDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes GoodRx Holdings, Inc. (GDRX) a Strong Momentum Stock: Buy Now?

GoodRx Holdings, Inc. (GDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Rising for GoodRx Holdings, Inc. (GDRX): Will It Gain?

GoodRx Holdings, Inc. (GDRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GDRX's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

After Golden Cross, GoodRx Holdings, Inc. (GDRX)'s Technical Outlook is Bright

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), the leading destination for prescription savings, today shared a report looking at the company's impact on social welfare as a result of helping millions of people access affordable medications. “The GoodRx Effect: How GoodRx is Changing the Economics of Healthcare” shows that by saving people money and improving medication adherence, GoodRx positively impacts health outcomes and significantly reduces costs within the healthcare syst.

The GoodRx Effect: Delivering a Transformative Impact on the U.S. Healthcare System through Prescription Savings

GoodRx Holdings, Inc. (GDRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings, today provided preliminary unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Revenue1,2 and Adjusted Revenue1,2 expected to be in the range of $195 million to $197 million Adjusted EBITDA Margin2,3 expected to be in the upper end of previous guidance range provided on November 9, 2.

GoodRx Announces Preliminary Fourth Quarter and Full Year 2023 Results and Early Expectations for First Quarter and Full Year 2024

Brookfield Infrastructure Partners L.P.

Chegg

ChargePoint Holdings

Raytheon Technologies

Smith & Wesson Brands

Taiwan Semiconductor Manufacturing

The 2024 presidential election promises to be volatile, and that volatility will doubtlessly carry over to your stock portfolio. Historically, elections can double stock market volatility, depending on a handful of variable factors, which makes election stocks important to watch.

Election Edge: 7 Stocks to Snag Before the 2024 Presidential Race Heats Up

GoodRx has been downgraded from ‘Buy' to ‘Underperform' by Bank of America (BoA) analysts on their concerns about competitive risks facing the company. They also lowered their price target from US$8 to US$4.50 citing “substantial uncertainty for GoodRx's future earnings profile.

GoodRx downgraded, price target slashed on competition concerns

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading resource for healthcare savings and information, today announced the election of Kelly J. Kennedy to its Board of Directors. Kennedy will serve as a member of the Board's audit committee and fill the seat left vacant by Jacqueline Kosecoff earlier this year. With over 25 years of experience serving in senior financial roles for leading retail and consumer brands, Kennedy brings extensive experience overseeing risk assessmen.

GoodRx Appoints Kelly J. Kennedy to Board of Directors

Whether you're looking for some relief from a stubborn headache or some vitamins to maintain your wellbeing, a good prescription app will get you what you need. In the latest edition of PYMNTS' Provider Ranking of Prescription Apps, we rank the best apps on the market to help you feel better faster.

GoodRX Dominates in Latest Provider Ranking of Prescription Apps

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading resource for healthcare savings and information, today announced that executives from the Company will participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time). The live webcast will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following.

GoodRx to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Advance Auto Parts

NVIDIA

Kulicke & Soffa Industries

This Analyst With 84% Accuracy Rate Sees Around 22% Upside In NVIDIA - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts - Advance Auto Parts (NYSE:AAP), GoodRx Holdings (NASDAQ:GDRX)

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading resource for healthcare savings and information, today announced that executives from the Company will participate in a fireside chat at the Evercore ISI HealthCONx Conference in Miami, FL on Thursday, November 30, 2023 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time). The live webcast will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following the conference, an.

GoodRx to Participate in the Evercore ISI HealthCONx Conference

Arcos Dorados Hlds

Barings BDC Inc

Coty

Cemex SAB de CV

Equitrans Midstream

Kosmos Energy

Navitas Semiconductor Corp

TETRA Technologies

Here are nine cheap stocks to buy now in a variety of sectors. While large-cap and mega-cap stocks receive much of the attention on Wall Street due to their safety and liquidity, many investors are limited in the number of shares they can buy.

9 Cheap Stocks to Buy Now (Under $10)

The online pharmacy company posted declines in both revenue and profitability in its third quarter. It met analyst estimates for net income but missed on the top line.

Why GoodRx Holdings Stock Dived by Nearly 19% Today

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, GoodRx Holdings, Inc. (GDRX) Q3 Earnings: A Look at Key Metrics

GoodRx Holdings, Inc. (GDRX) Q3 2023 Earnings Call Transcript

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), a leading resource for healthcare savings and information, has released its financial results for the third quarter 2023. Third Quarter 2023 Highlights Revenue1 of $180.0 million Adjusted Revenue1,2 of $190.0 million Net loss of $38.5 million; Net loss margin of 21.4% Adjusted Net Income2 of $25.5 million; Adjusted Net Income Margin2 of 13.4% Adjusted EBITDA2 of $53.5 million; Adjusted EBITD.

GoodRx Reports Third Quarter 2023 Results

Sanofi

GoodRx said on Thursday it has collaborated with Sanofi to offer the drugmaker's most-prescribed insulin injection Lantus for only $35 through its digital marketplace in the U.S.

News for GoodRx Holdings Stock (GDRX)